BOEHRINGER INGELHEIM VETMEDICA, INC. Patent applications |
Patent application number | Title | Published |
20150276737 | Immunogenic compositions including SIRS virus - Immunogenic compositions that include swine infertility and respiratory virus (“SRRS virus”) are provided herein. Also provided are kits for producing and using the immunogenic compositions. Vaccines and sera for treatment of SRRS, a method for producing the vaccine, methods for diagnosis of SRRS, and antibodies to the viral agent useful in diagnosis and treatment of SRRS are also provided. Swine infertility and respiratory virus is also referred to herein as Mystery Swine Disease (“MSD”). | 10-01-2015 |
20150093404 | PCV2 ORF2 PROTEIN VARIANT AND VIRUS LIKE PARTICLES COMPOSED THEREOF - Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation. | 04-02-2015 |
20150056248 | PORCINE CIRCOVIRUS TYPE 2 (PCV2) SUBUNIT VACCINE - Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype. | 02-26-2015 |
20140377298 | TREATMENT OF PIGS WITH PCV2 ANTIGEN - The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets. | 12-25-2014 |
20140365388 | PROTOCOL MANAGEMENT SYSTEM AND METHODS FOR LIVESTOCK OPERATIONS - The present disclosure provides systems and methods for developing and managing a protocol for use in a livestock operation. The method includes receiving, at a computing platform, input from a user, generating, using the computing platform, the protocol based on the user input, wherein the protocol includes at least one activity period including at least one action, and distributing the protocol to at least one end user. | 12-11-2014 |
20140363466 | METHOD OF TREATING PREGNANT COWS AND/OR HEIFERS - The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow. | 12-11-2014 |
20140341947 | IMMUNOGENIC COMPOSITIONS COMPRISING LAWSONIA INTRACELLULARIS - The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by | 11-20-2014 |
20140328877 | WEST NILE VIRUS VACCINE - The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates. | 11-06-2014 |
20140322267 | ORF2 PROTEIN OF PCV2 SUBTYPE A (PCV2A) FOR USE IN CROSS-PROTECTION - Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype a (PCV2a) ORF2 proteins or immunogenic compositions comprising a PCV2a ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype. | 10-30-2014 |
20140271698 | PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS, COMPOSITIONS, VACCINE AND METHODS OF USE - The present invention relates to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) mutant strains having increased stability; compositions containing the strains or antigens derived therefrom; vaccines containing the strains, including killed, attenuated or subunit vaccines; nucleic acids encoding PRRSV polypeptides, polypeptides encoded by the nucleic acids, including antigenic fragments thereof; antibodies which specifically bind to said polypeptides, and methods making and using thereof. | 09-18-2014 |
20140248603 | QUANTIFICATION OF VACCINE COMPOSITIONS - The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus. | 09-04-2014 |
20140234354 | PORCINE PARVOVIRUS 5B, METHODS OF USE AND VACCINE - The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus. | 08-21-2014 |
20140170180 | PORCINE PARVOVIRUS 5A, METHODS OF USE AND VACCINE - The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus. | 06-19-2014 |
20140127259 | COMPOSITIONS AND METHODS FOR VACCINATING CATTLE - The present invention relates to compositions, uses thereof, and methods of vaccinating cattle, particularly cows and heifers, against | 05-08-2014 |
20140050755 | NOVEL H5 PROTEINS, NUCLEIC ACID MOLECULES AND VECTORS ENCODING FOR THOSE, AND THEIR MEDICINAL USE - The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals. | 02-20-2014 |
20140011210 | ACTINOBACILLUS SUIS ANTIGENS - The invention provides immunogenic compositions useful for inhibiting, treating, protecting, or preventing infection by | 01-09-2014 |
20130302370 | REDUCTION OF CONCOMITANT INFECTIONS IN PIGS BY THE USE OF PCV2 ANTIGEN - The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. | 11-14-2013 |
20130273099 | PREVENTION AND TREATMENT OF SUB-CLINICAL PCVD - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs. | 10-17-2013 |
20130266613 | OUTER MEMBRANE PROTEINS OF HISTOPHILUS SOMNI AND METHODS THEREOF - The present invention relates to immunological compositions of outer membrane proteins (OMPs) of | 10-10-2013 |
20130202617 | HEMORRHAGIC FELINE CALICIVIRUS, CALICIVIRUS AND METHOD FOR PREVENTING CALICIVIRUS INFECTION OR DISEASE - The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen. | 08-08-2013 |
20130164332 | LAWSONIA VACCINE AND METHODS OF USE THEREOF - The present invention provides improved vaccination methods for increased protection against ileitis. The methods provide for the vaccination of young animals, preferably piglets, between 10 and 26 days of age, vaccination of pregnant sows during the second or third stages of gestation, and a combination of these methods. Vaccination of the pregnant sows can occur using repeated and/or high doses of | 06-27-2013 |
20130156811 | METHOD OF PREVENTING EARLY LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates inter alia to the use of a combination of a vaccine against | 06-20-2013 |
20130115236 | PROPHYLAXIS AND TREATMENT OF PRDC - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs. | 05-09-2013 |
20130101621 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 04-25-2013 |
20120237543 | EQUINE RHINITIS VACCINE - The disclosure provides for immunogenic compositions against Equine Rhinitis Virus, particularly Equine Rhinitis A and B Virus, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. | 09-20-2012 |
20120231027 | NOVEL H5 PROTEINS, NUCLEIC ACID MOLECULES AND VECTORS ENCODING FOR THOSE, AND THEIR MEDICINAL USE - The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals. | 09-13-2012 |
20120148620 | COMPOSITIONS AND METHODS FOR VACCINATING CATTLE - The present invention relates to compositions, uses thereof, and methods of vaccinating cattle, particularly cows and heifers, against | 06-14-2012 |
20120107348 | MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine, | 05-03-2012 |
20120093854 | USE OF MYCOPLASMA BOVIS ANTIGEN - The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused by | 04-19-2012 |
20110274710 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 11-10-2011 |
20110217327 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 09-08-2011 |
20110195088 | Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use - A method of predicting the virulence of a new or uncharacterized PRRS virus strain is provided wherein the strain is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and/or viremia magnitude of a PRRS virus strain of known virulence, as a measure of the virulence of the new or uncharacterized strain. | 08-11-2011 |
20110182935 | PREVENTION AND TREATMENT OF SUB-CLINICAL PCVD - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs. | 07-28-2011 |
20110159033 | WEST NILE VIRUS VACCINE - The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates. | 06-30-2011 |
20110150770 | MULTIVALENT VACCINE AGAINST PORCINE TESCHOVIRUS AND OTHER DISEASE CAUSING ORGANISMS IN SWINE - An immunogenic composition or vaccine, and method of treatment are provided by the present invention. The immunogenic composition is useful for treating, preventing, and lessening the severity of clinical symptoms associated with disease-causing organisms in swine, utilizing one or more Porcine Teschovirus antigen(s) along with an antigen of the other disease-causing organism in swine and a pharmaceutically acceptable carrier. | 06-23-2011 |
20110129495 | TREATMENT OF PRDC IN PIGS - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs. | 06-02-2011 |
20110123570 | ACTINOBACILLUS SUIS ANTIGENS - The invention provides immunogenic compositions useful for inhibiting, treating, protecting, or preventing infection by | 05-26-2011 |
20110117129 | Vaccine Against Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP PRRS) - The present invention is related to methods and attenuated viral compositions for use in preventing and treating a high fever disease forms associated with porcine reproductive and respiratory syndrome (PRRS), such as highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS), a viral disease affecting swine. | 05-19-2011 |
20110091499 | TREATMENT OF PIGS WITH PCV2 ANTIGENT - The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets. | 04-21-2011 |
20110059437 | PCR-BASED GENOTYPING | 03-10-2011 |
20110059126 | METHODS OF REDUCING VIRUCIDAL ACTIVITY IN PCV-2 COMPOSITIONS AND PCV-2 COMPOSITIONS WITH AN IMPROVED IMMUNOGENICITY - The present invention provides methods of reducing the vircidal activity of a composition comprising a PCV-2 antigen as well as antigenic preparations and immunogenic compositions comprising a PCV-2 antigen, wherein the virucidal activity has been reduced. In addition, the present invention also relates to a method of increasing the immunogenicity of an immunogenic composition comprising a PCV-2 antigen as well as immunogenic composition with an increased immunogenicity. | 03-10-2011 |
20110052629 | METHODS OF REDUCING CONCOMITANT INFECTIONS IN PIGS WITH A PCV2 ANTIGEN - The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. | 03-03-2011 |
20110033495 | METHODS AND COMPOSITIONS FOR REDUCING THE IMPACT OF ENTERIC DISEASES - The present invention relates to the use of an immunogenic composition that comprises a PCV2 antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with an enteric infection, even more preferably, with enteric disease. The use relates to a method comprising the steps of administering the composition to an animal in need thereof, preferably prior to disease exposure. Administration of PCV2 antigen, preferably ORF2 of PCV2, lessens the incidence and reduces the severity of the enteric disease. | 02-10-2011 |
20110020394 | PCV2 ORF2 VIRUS LIKE PARTICLE WITH FOREIGN AMINO ACID INSERTION - The present invention comprises methods and compositions related to the production and use of amino acid sequences. In particular, PCV2 ORF2 is shown to be useful as a virus-like particle which produces amino acid sequences that retain their immunogenicity or antigenicity when the DNA encoding the PCV2 ORF2 is inserted into an expression system. DNA sequences that are foreign to PCV2 can be attached “in-frame” to the ORF2 DNA and the entire sequence, including the DNA foreign to PCV2, is expressed. It was shown that such sequences retain their antigenicity and therefore their potential utility in immunogenic compositions. | 01-27-2011 |
20100272759 | MODIFIED LIVE VACCINE OF MYCOPLASMA BOVIS, METHODS OF PRODUCING MODIFIED LIVE MYCOPLASMA BOVIS VACCINES, COMBINATION VACCINES AND METHODS OF TREATMENT - The present invention relates to new attenuated | 10-28-2010 |
20100266637 | METHOD OF PREVENTING EARLY LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates inter alia to the use of a combination of a vaccine against | 10-21-2010 |
20100178301 | METHOD OF TREATING PREGNANT COWS AND/OR HEIFERS - The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow. | 07-15-2010 |
20100136060 | METHODS OF REDUCING PORCINE CIRCOVIRUS-ASSOCIATED DISEASE OUTBREAKS - The present invention relates to the use of an immunogenic composition that comprises a | 06-03-2010 |
20100129398 | Materials and Methods for Control of Porcine Reproductive and Respiratory Syndrome - Methods of reducing the severity of porcine reproductive and respiratory syndrome virus (PRRSV) infections, as well as, methods of preventing such infections are provided. The methods provide for the age-based innoculation of swine with PRRS antigen, preferably Ingelvac® ATP. | 05-27-2010 |
20100129397 | EFFECTIVE METHOD OF TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and | 05-27-2010 |
20100028860 | Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use - A method of predicting the virulence of a new or uncharacterized PRRS virus strain is provided wherein the strain is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and/or viremia magnitude of a PRRS virus strain of known virulence, as a measure of the virulence of the new or uncharacterized strain. | 02-04-2010 |
20100003278 | Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof - The present application describes improved an immunogenic compositions of virus vaccines wherein the virus vaccines comprise adjuvants selected from the group consisting of MCP-1, | 01-07-2010 |
20090317423 | PCV2 MYCOPLASMA HYOPNEUMONIAE IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of M. hyo infection, preferably M. hyo bacterin, or an immunogenic composition comprising M. hyo bacterin, and at least one immunogenic active component of another disease-causing organism in swine, preferably PCV2 wherein the preferred PCV2 antigen for such a multivalent vaccine is PCV2 ORF 2 protein. | 12-24-2009 |
20090215698 | LAWSONIA PROTEIN USEFUL AS A COMPONENT IN SUBUNIT VACCINE AND METHODS OF MAKING AND USING THEREOF - The present invention provides nucleic acid and amino acid sequences useful as the immunogenic portion of vaccines or immunogenic compositions effective for lessening the severity of the clinical symptoms associated with | 08-27-2009 |
20090148474 | PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME ISOLATES AND METHODS OF USE - A method of predicting the virulence of a new or uncharacterized PRRS virus isolate is provided wherein the isolate is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and/or viremia magnitude of a PRRS virus isolate of known virulence, as a measure of the virulence of the new or uncharacterized isolate. Additionally, a method of selecting an isolate for inclusion in an immunogenic composition based on the predicted virulence is also provided, together with compositions incorporating attenuated forms of viruses predicted to be virulent. | 06-11-2009 |
20090130148 | MYCOPLASMA BOVIS VACCINE AND METHODS OF USE THEREOF - The present invention relates to new attenuated | 05-21-2009 |
20090098158 | REDUCTION OF CONCOMITANT INFECTIONS IN PIGS BY THE USE OF PCV2 ANTIGEN - The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. | 04-16-2009 |
20090092636 | MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine, | 04-09-2009 |
20090068223 | COMBINATION VACCINE COMPRISING AN ATTENUATED BOVINE VIRAL DIARRHEA VIRUS - The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the prophylaxis and treatment of BVDV caused infections, and a further immunological active component for the prophylaxis and treatment of microbiological infections other than BVDV. | 03-12-2009 |
20090022752 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 01-22-2009 |
20090022751 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 01-22-2009 |
20090022750 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 01-22-2009 |
20090022749 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 01-22-2009 |
20090016992 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 01-15-2009 |
20090010954 | PREVENTION AND TREATMENT OF SUB-CLINICAL PCVD - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs. | 01-08-2009 |
20080305128 | TREATMENT OF PRDC IN PIGS - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs. | 12-11-2008 |
20080279889 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 11-13-2008 |
20080279876 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 11-13-2008 |
20080279875 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 11-13-2008 |
20080267995 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 10-30-2008 |
20080261887 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 10-23-2008 |
20080260779 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 10-23-2008 |
20080241190 | VACCINATION OF HORSES AGAINST LAWSONIA INTRACELLULARIS - The present invention is broadly concerned with vaccination of horses against proliferative enteritis, preferably equine proliferative ileitis, which is caused by an obligate intracellular bacterium Lawsonia Intracellularis (L. intracellularis). Specifically, the invention provides for a method of providing immune protection against L. intracellularis by vaccinating horses, preferably foals starting from one (1) week of age. Preferably the foals are vaccinated with about 4.9 log 10 to about 6.9 log 10 of a live modified L. intracellularis bacteria per dose. | 10-02-2008 |
20080226669 | MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine, | 09-18-2008 |